Bausch + Lomb Corp's stock is facing challenges after disappointing trial results, leading to a notable decline in its share price.
Shares of Bausch + Lomb Corp (BLCO.TO) fell 1.13% in the last trading session, closing at CA$22.70. This drop follows significant news about the company's experimental glaucoma treatment, which did not meet its primary goals in clinical trials, resulting in a halt to its development.
Investor takeaway: Investors should be cautious as Bausch + Lomb navigates setbacks in its drug pipeline, especially with the halted glaucoma treatment. While the ophthalmology market is growing, the company's recent challenges raise questions about its immediate prospects.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.45B
52W high
$25.70
52W low
$18.76
1W change
+3.00%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 7.3% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.39
+7.3% Upside
Current Price
C$23.66
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
35.9%
Annualized
90-Day Vol
30.9%
Annualized
Trend (90d)
+31.9%
Annualized drift
90d Mean
C$26.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.58 | C$21.72 – C$27.81 |
| 60 trading days | C$25.53 | C$21.43 – C$30.41 |
| 90 trading days | C$26.51 | C$21.40 – C$32.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bausch + Lomb Corp shares drop 1.13% in one day.
The stock is now trading significantly below its 52-week high, reflecting investor uncertainty following recent trial failures.
Bull case
Despite recent setbacks, Bausch + Lomb operates in a growing ophthalmology market that is projected to expand significantly due to rising demand for eye care solutions. The company has a diversified pipeline and continues to innovate, which could lead to future successes.
Bear case
The failure of the BL1107 glaucoma treatment is a major setback for Bausch + Lomb's pipeline and market confidence. Along with ongoing losses and governance concerns, the stock's recent performance suggests potential volatility ahead.
Recent Developments
Advertisement
Bausch + Lomb's announcement about the failure of its BL1107 glaucoma treatment has sharply declined investor confidence. The company had hoped this treatment would generate significant revenue, with projected peak sales of around $800 million annually. However, the inability to replicate earlier positive results has forced the company to change its strategy, focusing instead on a sustained-release implant for a different condition.
Market Reaction
The stock's decline reflects broader investor sentiment, particularly in the healthcare sector, where stocks have been under pressure. The NYSE Healthcare Index also showed a decrease, indicating that Bausch + Lomb's struggles are part of a larger trend affecting healthcare stocks. Investors are advised to monitor the company's upcoming trials and product developments closely.
Future Outlook
While Bausch + Lomb has a diversified pipeline and operates in a growing market, the recent setbacks raise questions about its ability to recover and generate profits in the near term. Investors should weigh the potential for future growth against the backdrop of recent failures and ongoing market volatility.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
